A Phase 1 interventional study of Cohort A and Cohort B in Healthy, sponsored by Uniquity One (UNI). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Uniquity One (UNI) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 1 Randomized, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Bioavailability of NSI-8226 in Healthy Participants.
Uniquity One (UNI) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
1. At the time of initial screening, in general good health (age 18 to 65 years);
Key Exclusion Criteria:
NSI-8226
Biological: Cohort A
NSI-8226
Biological: Cohort B
NSI-8226
Biological: Cohort C
NSI-8226
Biological: Cohort D
Administered IV High dose
Administered SC Low Dose
Administered SC Mid Dose
Administered SC High Dose
Safety and tolerability
To evaluate the incidence of treatment emergent adverse events of NSI-8826 in healthy participants according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0
Time frame: 140 days
Absolute bioavailability
Pharmacokinetics (PK) and absolute bioavailability of NSI-8226 in healthy participants.
Time frame: 140 days
Concentration of immunogenicity
Immunogenicity profile of NSI-8226 in healthy participants.
Time frame: 140 days
Parameters in healthy participants
Pharmacodynamic (PD) parameters of NSI-8226 in healthy participants.
Time frame: 140 days
Ran from Apr 2024 to primary completion in Oct 2024, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uniquity One (UNI)